Research programme: BLI 1008 - BioliteAlternative Names: BLI-1008
Latest Information Update: 16 Jul 2016
At a glance
- Originator BioLite Inc
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Attention-deficit-hyperactivity-disorder in Taiwan
- 30 Jan 2013 Preclinical trials in Attention-deficit hyperactivity disorder in Taiwan (unspecified route)